Actively Recruiting
Imaging PARP Expression Using 18FFTT PETCT to Predict Response to Gemcitabine, Cisplatin, and Durvalumab in Newly Diagnosed Cholangiocarcinoma
Led by University of Washington · Updated on 2026-10-20
22
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether the imaging agent 18FFTT can be used with PETCT scans to predict how patients with newly diagnosed cholangiocarcinoma will respond to the combination treatment of gemcitabine, cisplatin, and durvalumab GCD. This phase II trial focuses on detecting PARP1 expression in tumor cells, which may influence treatment response. PETCT combines two imaging methods PET uses radioactive tracers like 18FFTT to create detailed pictures, while CT provides precise images of organs and tissues. Patients receive an intravenous injection of 18FFTT and then undergo PETCT scans at 60, 90, or 150 minutes after injection, within 30 days before starting GCD and again 12 weeks after treatment begins if no severe side effects occur. Throughout the study, patients also have CT andor MRI scans. After finishing the interventions, participants are followed up at week 24 and for up to six months after completing GCD therapy. During the study, researchers measure how much 18FFTT is taken up by tumors using standardized uptake values SUVmax and SUVmean at baseline and during follow-up. These measurements are compared to treatment responses to see if 18FFTT PETCT can predict outcomes. Participants undergo various imaging scans and must comply with study procedures and contraception requirements if applicable. The study includes safety monitoring and aims to improve understanding of treatment response in cholangiocarcinoma.
CONDITIONS
Brief Title
[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma
Research Team
A
Angela Castellanos Rodriguez, MD, MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here